Integra LifeSciences Holdings Corporation (IART) — ESG & Values Scores

Environment story

Integra LifeSciences discloses limited environmental metrics in its 10-K filing. The company acknowledges compliance with environmental, health and safety regulations and has established EHS management systems, but provides no quantified Scope 1, 2, or 3 emissions data, renewable energy percentages, or net-zero targets. This lack of disclosure triggers mandatory deductions under the deterministic rubric. The company does not reference carbon offset reliance, but the absence of disclosed operational decarbonization initiatives and emissions targets after 2045 (or any stated target) results in significant point reductions. The filing mentions compliance with evolving environmental regulations but does not position the company as a climate leader. No material environmental controversies (toxic waste, water consumption disputes, or habitat litigation) are documented in the provided 10-K excerpt.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Environmental Health and Safety Management Systems

Company implements EHS procedures globally, with centrally led organizational structure for compliance with Employee Health & Safety laws and environmental regulations. Mentions compliance with country-specific, federal, state and local laws governing use, manufacture, storage, handling and disposal of hazardous materials.

Operational compliance framework; no quantified decarbonization or emissions reduction targets disclosed.
Facility Compliance Programs

Manufacturing facilities subject to FDA Quality Management System Regulations and periodic inspections. Company maintains compliance procedures for environmental, health and safety standards across global operations.

Regulatory adherence only; no voluntary emissions reduction or sustainability leadership demonstrated.

Social story

Integra LifeSciences demonstrates moderate social practices with disclosed workforce development, health and safety commitments, and compensation equity focus. As of December 31, 2025, the company employed 4,427 regular full and part-time employees globally (69.6% U.S.-based). The company reports commitment to pay equity analysis and market-competitive compensation without regard to protected characteristics, and offers comprehensive benefits programs including health insurance, disability coverage, parental leave, and wellness initiatives. Eight employee-led Business Resource Groups (BRGs) are in place to support career development and diversity initiatives. However, the filing discloses no specific CEO-to-median-worker pay ratio, no quantified leadership diversity percentages (executive/board), no union standing information, no documented union-suppression activities or recent strikes, and no supply-chain audit findings regarding human-rights hazards. The absence of these critical data points prevents full scoring under the deterministic rubric, though no active union-suppression or strike activity is documented as contraindications.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Employee Compensation and Benefits Philosophy

Market-competitive compensation benchmarked against peer companies; annual and long-term incentive packages linked to business and individual performance. Pay equity analysis conducted regularly; compensation decisions made without regard to gender, race, color, national or ethnic origin, age, disability, sexual orientation, gender identity, genetic information, religion, or veteran status.

Formal commitment to fair pay and compensation equity; no quantified CEO-to-worker ratio or pay gap data disclosed.
Talent Development and Retention Programs

Comprehensive human capital development programs including experiential, collaborative, and formal learning. Employees encouraged to discuss skills and career advancement with managers; external job-specific development programs funded by company. Focus on attracting top talent through refined recruiting and hiring processes.

Structured employee development framework; supports retention and professional growth.
Employee Health and Safety Management

Commitment to safe environment supported by EHS management systems. Global implementation via regional and country-level coordinators; Incident Procedure Policy and General Safety Rules guide workplace safety. Managers responsible for compliance with local laws and safety standards.

Proactive safety culture and risk reduction; no quantified safety metrics or incident rates disclosed.
Employee Engagement and Wellbeing

Annual global engagement pulse surveys conducted and results shared with senior management and departments. Health and wellbeing programs vary by country; benefits include comprehensive health insurance, disability coverage, parental leave, employee assistance programs, fitness reimbursement, digital health solutions, weight management, smoking cessation, substance use disorder helpline, and diabetes health program.

Demonstrates commitment to employee feedback loop and holistic wellbeing; programs adapted based on survey results.
Business Resource Groups (BRGs)

Eight Integra-sponsored, employee-led BRGs provide career development, leadership opportunities, and networking connections across the organization.

Supports diversity, inclusion, and professional development for underrepresented groups.

Governance story

Integra LifeSciences provides limited governance transparency in its 10-K filing. The company does not disclose board independence percentage, share structure details (single vs. dual-class), annual lobbying expenditures, or active regulatory proceedings (antitrust, consumer-safety, financial-fraud). The filing extensively documents regulatory compliance obligations (FDA, HIPAA, GDPR, etc.) and notes FDA inspections, warning letters, and product recalls as historical risks, but does not itemize current significant active proceedings. No evidence of dual-class voting structures is apparent from the filing. No lobbying disclosure targeting environmental deregulation or consumer-protection rollback is documented. The absence of affirmative governance disclosures across board independence, lobbying spend, and current regulatory fines prevents full scoring, though no major red flags (antitrust litigation, SEC consent decrees, shareholder voting disputes) are documented as active issues.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Regulatory Compliance Framework

Comprehensive compliance procedures for FDA Quality Management System Regulations, HIPAA, GDPR, EU MDR, and other jurisdictional requirements. Compliance Master Plan (CMP) initiated in 2024 to remediate quality system gaps, harmonize QMS, and enhance quality culture across manufacturing and supply network.

Systematic approach to regulatory adherence; demonstrates commitment to quality systems and compliance governance.
Global Code of Conduct and Corporate Governance

Corporate governance information including certificate of incorporation, bylaws, corporate governance guidelines, board committee charters, and global code of conduct available on investor relations website under 'Corporate Governance' heading.

Transparent governance documentation framework; available to shareholders for review.
Data Privacy and Cybersecurity Compliance

Compliance with HIPAA, GDPR, UK GDPR, CCPA, and other data privacy laws. Company acknowledges obligations to third-party service providers and recognizes EU AI Act and state AI law compliance as increasing cost and complexity.

Proactive governance of data protection and emerging AI regulation; reflects evolving regulatory landscape.
Healthcare Fraud and Abuse Compliance

Compliance with Anti-Kickback Statute, False Claims Act, HIPAA fraud provisions, state anti-kickback laws, Physician Payments Sunshine Act (Open Payments), and FCPA. Company emphasizes careful design of sales and marketing practices to avoid healthcare fraud violations.

Comprehensive healthcare compliance program; reflects commitment to regulatory adherence in high-scrutiny sector.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Integra LifeSciences Holdings Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Integra LifeSciences Holdings Corporation in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)